These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Study on the prostatic tissue levels of cefmenoxime (CMX)].
    Author: Kataoka K, Kaneko S, Kurita T.
    Journal: Hinyokika Kiyo; 1985 Feb; 31(2):273-9. PubMed ID: 2409786.
    Abstract:
    The concentrations of Cefmenoxime (CMX) were examined in the serum and prostatic tissue of 25 patients with benign prostatic hypertrophy and of 1 patient with prostatic carcinoma. The CMX levels were measured at scheduled intervals after 2 g CMX administration by one hour drip infusion prior to prostatectomy. Pharmacokinetic analysis was performed based on the two compartment open model theory. 1) Maximum serum level of CMX was 124 micrograms/ml at the end of drip infusion and the biological half-life was 1.07 hrs. 2) CMX concentration in prostatic tissue reached a maximum level of 35.7 cg/g at 1.16 hrs after the start of CMX administration. Ratio of prostatic tissue to serum level in the area under curve (AUC) was 33% and biological half-life was 1.07 hrs. These results suggested that the CMX concentration in the prostatic tissue was higher than the MIC80 against pathogenic bacteria, particularly E.coli and Klebsiella sp. for a relatively long time. For this reason CMX is one of the more preferred drugs for treatment of chronic prostatitis and post-operative infection of prostate.
    [Abstract] [Full Text] [Related] [New Search]